ArticlePharmaceutical research2026
Solid-State Stability of Pentobarbital in Fast-Dissolving Suppositories: Implications for Dissolution Behavior and Pediatric Formulation Performance.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSafe and well-tolerated sedative formulations are essential in pediatric procedural care. Pentobarbital, a short-acting barbiturate, remains widely used for pediatric sedation. However, its oral administration is limited by poor palatability. Rectal administration therefore represents a relevant alternative, provided that formulation stability is ensured. This study evaluated the physicochemical and microbiological stability of fast-dissolving pentobarbital suppositories developed for pediatric use.
methodsSuppositories containing 30 or 60 mg of pentobarbital sodium were formulated with two sodium hydroxide (NaOH) concentrations and stored under refrigerated (5°C) or frozen (-20°C) conditions for up to 180 days. Stability was assessed by macroscopic examination, pH measurement, dissolution testing, mechanical strength, softening time, and microbiological quality. Solid-state changes were analyzed using Raman spectroscopy and X-ray diffraction, and precipitation kinetics were modeled.
resultsRefrigerated storage led to progressive precipitation from day 90, associated with pH decrease and conversion of pentobarbital sodium to its free acid, resulting in incomplete dissolution. In contrast, frozen storage preserved pH, physical integrity, and complete dissolution, even after 30 days at 5°C following thawing. Spectroscopic and diffraction analyses confirmed recrystallization under refrigeration, whereas frozen formulations retained an amorphous structure. Increased NaOH content delayed, but did not prevent, instability at 5°C. All formulations complied with pharmacopeial mechanical and microbiological requirements.
conclusionStorage temperature was the main determinant of stability, with freezing ensuring long-term preservation. NaOH buffering mitigated gelatin acidity and delayed drug conversion, thereby extending shelf life. These findings support further biopharmaceutical and clinical evaluation of pentobarbital suppositories for pediatric sedation.
Indexed as
Identifiers
41776151What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.